Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study | Zendy

Valentina Boni | Zendy; Barbara Pistilli | Zendy; Irene Braña | Zendy; Geoffrey I. Shapiro | Zendy; José Trigo | Zendy; Víctor Moreno | Zendy; Daniel Castellano | Zendy; Cristian Fernández | Zendy; Carmen Kahatt | Zendy; Vicente Alfaro | Zendy; Mariano Siguero | Zendy; Ali Zeaiter | Zendy; Frida Longo | Zendy; Khalil Zaman | Zendy; A. Antón | Zendy; Alfredo Paredes | Zendy; G. Huidobro | Zendy; Vivek Subbiah | Zendy

Open Access

Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study

Author(s) -

Valentina Boni,

Barbara Pistilli,

Irene Braña,

Geoffrey I. Shapiro,

José Trigo,

Víctor Moreno,

Daniel Castellano,

Cristian Fernández,

Carmen Kahatt,

Vicente Alfaro,

Mariano Siguero,

Ali Zeaiter,

Frida Longo,

Khalil Zaman,

A. Antón,

Alfredo Paredes,

G. Huidobro,

Vivek Subbiah

Publication year - 2022

Publication title -

esmo open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.409

H-Index - 31

ISSN - 2059-7029

DOI - 10.1016/j.esmoop.2022.100571

Subject(s) - medicine , metastatic breast cancer , breast cancer , adverse effect , oncology , clinical endpoint , phases of clinical research , nausea , response evaluation criteria in solid tumors , confidence interval , cancer , clinical trial

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog